Investors in cash trouble should check out Akero Therapeutics Inc (AKRO)

With 0.85 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.2 million shares. The 52-week range on AKRO shows that it touched its highest point at $58.40 and its lowest point at $17.86 during that stretch. It currently has a 1-year price target of $78.27. Beta for the stock currently stands at -0.22.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKRO was up-trending over the past week, with a rise of 5.30%, but this was up by 107.19% over a month. Three-month performance surged to 75.37% while six-month performance rose 93.87%. The stock gained 139.78% in the past year, while it has gained 86.34% so far this year. A look at the trailing 12-month EPS for AKRO yields -3.75 with Next year EPS estimates of -4.77. For the next quarter, that number is -1.16. This implies an EPS growth rate of -37.36% for this year and -20.04% for next year. EPS is expected to decline by -19.08% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 1.03%.

Float and Shares Shorts:

At present, 69.61 million AKRO shares are outstanding with a float of 66.61 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKRO since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.83041 being high and -$4.24828 being low. For AKRO, this leads to a yearly average estimate of -$3.9697. Based on analyst estimates, the high estimate for the next quarter is -$0.93 and the low estimate is -$1.25. The average estimate for the next quarter is thus -$1.11.